-
公开(公告)号：US20140309216A1
公开(公告)日：2014-10-16
申请号：US14316166
申请日：2014-06-26
Applicant: F.HOFFMANN-LA ROCHE AG , GENENTECH, INC.
Inventor： Adrian Folkes , Stephen Shuttleworth , Irina Chuckowree , Sally Oxenford , Nan Chi Wan , Georgette Castanedo , Richard Goldsmith , Janet Gunzer-Toste , Tim Heffron , Simon Mathieu , Alan Olivero , Daniel P. Sutherlin , Bing-Yan Zhu
IPC: C07D495/04 , A61K45/06 , A61K31/551 , A61K31/5377 , C07D491/048
CPC classification number: A61K31/5377 , A61K31/551 , A61K45/06 , C07D491/04 , C07D491/048 , C07D495/04
Abstract: Compounds of Formulae Ia, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
Abstract translation: 式Ia化合物和立体异构体，几何异构体，互变异构体，溶剂合物，代谢物和药学上可接受的盐可用于抑制脂质激酶（包括PI3K）和用于治疗由脂质激酶介导的癌症等疾病。 公开了将式Ia化合物用于体外，原位和体内诊断，预防或治疗哺乳动物细胞或相关病理条件中的这种病症的方法。
-
公开(公告)号：US12071425B2
公开(公告)日：2024-08-27
申请号：US17275606
申请日：2019-09-12
Applicant: Genentech, Inc.
Inventor： Marie-Gabrielle Braun , Cuong Q. Ly , Georgette Castanedo , Paul Gibbons , Wendy Lee , Joachim Rudolph , Nicole Alice Blaquiere , Jacob Bradley Schwarz , Ramsay Beveridge , Jean-Philippe Leclerc , Alexandre Lemire , Leo Fu
IPC: C07D401/14 , A61K45/06 , C07D401/04 , C07D413/14 , C07D471/04 , C07D471/08
CPC classification number: C07D401/14 , A61K45/06 , C07D401/04 , C07D413/14 , C07D471/04 , C07D471/08
Abstract: Described herein are phenoxy-pyridyl-pyrimidine compounds with inositol requiring enzyme 1 (IRE1) modulation activity or function having the Formula I structure or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such IRE1 modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
-
公开(公告)号：US11279735B2
公开(公告)日：2022-03-22
申请号：US16816969
申请日：2020-03-12
Applicant: Genentech, Inc.
Inventor： Emily J. Hanan , Georgette Castanedo , Marie Gabrielle Braun , Keira Garland , Peter Andrew Smith , Richard Pastor , Paul Gibbons , Yunxing Cheng , Guosheng Wu , Yuhong Fu , Po-Wai Yuen
Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of lipoprotein signal peptidase II (LspA), a key protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.
-
公开(公告)号：US20150166569A1
公开(公告)日：2015-06-18
申请号：US14622446
申请日：2015-02-13
Applicant: Genentech, Inc.
Inventor： Steven Staben , Georgette Castanedo , Christian A.G.N. Montalbetti , Jianwen Feng
IPC: C07D498/04 , C07D513/04 , C07D519/00 , C07D487/04
CPC classification number: C07D498/04 , C07D487/04 , C07D498/00 , C07D498/12 , C07D513/04 , C07D519/00
Abstract: The invention relates to novel compounds of Formula I: wherein A1, A2, A3, A4, A5, A6, R2, R4, R5, R6, R7, R8 and subscripts m and n each has the meaning as described herein. Compounds of Formula I and pharmaceutical compositions thereof are useful in the treatment of disease and disorders in which undesired or over-activation of NF-kB signaling is observed.
Abstract translation: 本发明涉及式I的新化合物：其中A1，A2，A3，A4，A5，A6，R2，R4，R5，R6，R7，R8和下标m和n各自具有本文所述的含义。 式I化合物及其药物组合物可用于治疗观察到NF-kB信号传导的不期望或过度活化的疾病和病症。
-
公开(公告)号：US20150065482A1
公开(公告)日：2015-03-05
申请号：US14466153
申请日：2014-08-22
Applicant: Genentech, Inc.
Inventor： Nicole Blaquiere , Georgette Castanedo , Jianwen A. Feng , Baihua Hu , Steven Staben , Po-wai Yuen , Guosheng Wu , Jason Burch
IPC: C07D513/04 , C07D471/04 , C07D403/10 , C07D401/14 , C07D413/10 , C07D491/052 , C07D487/04 , C07D401/10
CPC classification number: C07D513/04 , C07D401/10 , C07D401/14 , C07D403/10 , C07D403/14 , C07D413/10 , C07D413/14 , C07D417/10 , C07D471/04 , C07D487/04 , C07D491/048 , C07D491/052 , C07D495/04
Abstract: The invention relates to compounds of Formula (0): wherein Q, A1-A8, R4 and R5 and each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.
Abstract translation: 本发明涉及式（O）的化合物：其中Q，A1-A8，R4和R5各自具有如本文所述的含义。 式（0）的化合物及其药物组合物可用于治疗其中观察到NF-kB信号传导的不期望或过度活化的疾病和病症。
-
Patent Agency Ranking
公开(公告)号：US09943519B2
公开(公告)日：2018-04-17
申请号：US14316166
申请日：2014-06-26
Applicant: F.HOFFMANN-LA ROCHE AG , GENENTECH, INC.
Inventor： Adrian Folkes , Stephen Shuttleworth , Irina Chuckowree , Sally Oxenford , Nan Chi Wan , Georgette Castanedo , Richard Goldsmith , Janet Gunzer-Toste , Tim Heffron , Simon Mathieu , Alan Olivero , Daniel P. Sutherlin , Bing-Yan Zhu
IPC: C07D413/14 , A61K31/535 , A61K31/5377 , C07D491/04 , C07D495/04 , A61K31/551 , A61K45/06 , C07D491/048
CPC classification number: A61K31/5377 , A61K31/551 , A61K45/06 , C07D491/04 , C07D491/048 , C07D495/04
Abstract: Compounds of Formulae Ia, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
-
公开(公告)号：US20170210724A1
公开(公告)日：2017-07-27
申请号：US15481852
申请日：2017-04-07
Applicant: Genentech, Inc.
Inventor： Nicole Blaquiere , Georgette Castanedo , Jianwen A. Feng , Baihua Hu , Steven Staben , Po-wai Yuen , Guosheng Wu , Xingyu Lin , Jason Burch
IPC: C07D401/10 , C07D401/14 , C07D491/107 , C07D409/14 , C07D405/14 , C07D495/04 , C07D495/06 , C07D471/04 , C07D487/04 , C07D413/10 , C07D403/10 , C07D405/10 , C07D417/14 , C07D491/048 , C07D413/14
CPC classification number: C07D401/10 , A61K31/395 , C07D401/14 , C07D403/10 , C07D403/14 , C07D405/10 , C07D405/14 , C07D409/14 , C07D413/10 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07D491/048 , C07D491/107 , C07D495/04 , C07D495/06
Abstract: The invention relates to compounds of Formula (0): wherein A1-A8, R4 and R5 each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.
-
公开(公告)号：US20170145034A1
公开(公告)日：2017-05-25
申请号：US15425698
申请日：2017-02-06
Applicant: Genentech, Inc.
Inventor： Nicole Blaquiere , Georgette Castanedo , Jianwen A. Feng , Baihua Hu , Steven Staben , Po-wai Yuen , Guosheng Wu , Jason Burch
IPC: C07D513/04 , C07D401/14 , C07D491/052 , C07D471/04 , C07D413/10 , C07D491/048 , C07D403/14 , C07D413/14 , C07D495/04 , C07D487/04 , C07D417/10 , C07D403/10 , C07D401/10
CPC classification number: C07D513/04 , C07D401/10 , C07D401/14 , C07D403/10 , C07D403/14 , C07D413/10 , C07D413/14 , C07D417/10 , C07D471/04 , C07D487/04 , C07D491/048 , C07D491/052 , C07D495/04
Abstract: The invention relates to compounds of Formula (0): wherein Q, A1-A8, R4 and R5 and each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.
-
公开(公告)号：US20160096850A9
公开(公告)日：2016-04-07
申请号：US14466153
申请日：2014-08-22
Applicant: Genentech, Inc.
Inventor： Nicole Blaquiere , Georgette Castanedo , Jianwen A. Feng , Baihua Hu , Steven Staben , Po-wai Yuen , Guosheng Wu , Jason Burch
IPC: C07D513/04 , C07D471/04 , C07D403/10 , C07D401/14 , C07D413/10 , C07D491/052 , C07D487/04 , C07D401/10
CPC classification number: C07D513/04 , C07D401/10 , C07D401/14 , C07D403/10 , C07D403/14 , C07D413/10 , C07D413/14 , C07D417/10 , C07D471/04 , C07D487/04 , C07D491/048 , C07D491/052 , C07D495/04
Abstract: The invention relates to compounds of Formula (0): wherein Q, A1-A8, R4 and R5 and each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.
-
公开(公告)号：US08993563B2
公开(公告)日：2015-03-31
申请号：US13738829
申请日：2013-01-10
Applicant: Genentech, Inc. , F. Hoffmann-la Roche AG
Inventor： Tracy Bayliss , Irina Chuckowree , Adrian Folkes , Sally Oxenford , Nan Chi Wan , Georgette Castanedo , Richard Goldsmith , Janet Gunzner , Tim Heffron , Simon Mathieu , Alan Olivero , Steven Staben , Daniel P. Sutherlin , Bing-Yan Zhu
IPC: A61K31/519 , C07D495/04 , C07D413/14 , A61K31/5377 , C07D491/04
CPC classification number: A61K31/5377 , A61K31/519 , C07D413/14 , C07D491/04 , C07D495/04
Abstract: Compounds of Formulas Ia-d where X is S or O, mor is a morpholine group, and R3 is a monocyclic heteroaryl group, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for modulating the activity of lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia-d for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
Abstract translation: 式Ia-d的化合物，其中X是S或O，mor是吗啉基团，R3是单环杂芳基，并且包括立体异构体，几何异构体，互变异构体，溶剂合物，代谢物和药学上可接受的盐可用于调节 脂质激酶（包括PI3K）的活性，以及用于治疗脂质激酶介导的疾病如癌症。 公开了使用式Ia-d的化合物在体外，原位和体内诊断，预防或治疗哺乳动物细胞或相关病理状况中的这种病症的方法。
-
-
-
-
-
-
-
-
-
Search Results
22
records
(took 0.054 seconds)
